Mutations in the gene encoding the ␥ 2 subunit of the AMP-activated protein kinase (AMPK) have recently been shown to cause cardiac hypertrophy and ventricular pre-excitation (Wolff-Parkinson-White syndrome). We have examined the effect of four of these mutations on AMPK activity. The mutant ␥ 2 polypeptides are all able to form functional complexes following co-expression with either ␣ 1  1 or ␣ 2  1 in mammalian cells. None of the mutations caused any detectable change in the phosphorylation of threonine 172 within the ␣ subunit of AMPK. Consequently, in the absence of an appropriate stimulus the mutant complexes, like the wild-type complex, exist in an inactive form demonstrating that the mutations do not lead to constitutive activation of the kinase. Three of the mutations we studied occur within the cystathionine -synthase (CBS) domains of ␥ 2 . Two of these mutations lead to a marked decrease in AMP dependence, whereas the third reduces AMP sensitivity. These findings suggest that the CBS domains play an important role in AMP-binding within the complex. In contrast, a fourth mutation, which lies between adjacent CBS domains, has no significant effect on AMPK activity in vitro. These results indicate that mutations in ␥ 2 have different effects on AMPK function, suggesting that they may lead to abnormal development of the heart through distinct mechanisms.The AMP-activated protein kinase (AMPK) 1 is the central component of a protein kinase cascade that plays a pivotal role in the regulation of energy metabolism (1). In response to activation following an increase in the AMP/ATP ratio, AMPK phosphorylates a number of downstream targets culminating in the switching off of energy (ATP)-utilizing pathways and the switching on of energy-generating pathways (1, 2). Activation of AMPK is complex and involves direct allosteric activation of the enzyme by AMP as well as phosphorylation, catalyzed by an upstream kinase, AMPK kinase (AMPKK) (3, 4). AMPK is a heterotrimeric complex, consisting of a catalytic subunit (␣) and two regulatory subunits ( and ␥) (5, 6) and isoforms of all three subunits have been identified (7-9). Although there is compelling evidence indicating that formation of the heterotrimeric complex is necessary for significant kinase activity (6, 10) the precise role of the regulatory subunits remains unclear. In addition, at present our understanding of the physiological relevance of the different subunit isoforms is very limited.Several groups have reported recently the identification of six different mutations in the ␥2 subunit from patients with cardiac hypertrophy and associated electrophysiologic abnormalties (11-14). All six mutations result in amino acid substitutions and are located within the C-terminal half of the protein. The mutations lead to the development of aberrant conduction systems, including pre-excitation, characteristic of Wolff-Parkinson-White syndrome (15) and in all but one case, the mutations also result in severe cardiac hypertrophy. No evidence of cardiac hypertro...